4.5 Article

Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study

Journal

ORPHANET JOURNAL OF RARE DISEASES
Volume 17, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13023-022-02301-0

Keywords

Haemophilia A; Haemophilia B; Direct medical costs; Societal costs; Productivity; Quality of life; Children

Funding

  1. Sanofi
  2. Bayer
  3. Roche
  4. Swedish Orphan Biovitrum AB
  5. Novo Nordisk
  6. SHIRE

Ask authors/readers for more resources

Haemophilia imposes a significant burden on children and their caregivers, both economically and humanistically. The medical and social costs are higher for severe haemophilia compared to moderate haemophilia. The overall quality of life is negatively affected by haemophilia.
Background Haemophilia bears substantial humanistic and economic burden on children and their caregivers. Characterising the differential impact of severe versus moderate paediatric haemophilia is important for clinical and health policy decisions. We analysed health-related quality of life (HRQoL), annual direct medical (excluding factor treatment costs), non-medical and societal costs among children and adolescents with moderate and severe haemophilia A or B without inhibitors from the European CHESS-PAEDs study. Information was reported by physicians and caregivers; patients aged >= 8 years self-reported their HRQoL. Descriptive statistics summarised demographic and clinical characteristics, costs, and HRQoL scores (EQ-5D-Y). Regression models estimated differences in HRQoL and costs for moderate versus severe haemophilia adjusting for age, body mass index z-score, country, number of comorbidities, and weight-adjusted annual clotting factor consumption. Results The analytic sample comprised 794 patients with a mean age of 10.5 years; most had haemophilia A (79%) and 58% had severe haemophilia. Mean predicted direct medical costs in moderate patients were two-thirds of the predicted costs for severe disease (euro3065 vs. euro2047; p < 0.001; N = 794), while societal costs were more than half of the predicted costs for children with severe haemophilia (euro6950 vs. euro3666; p < 0.001; N = 220). Mean predicted HRQoL scores were 0.74 and 0.69 for moderate and severe disease, respectively (p < 0.05; N = 185). Conclusion Children with haemophilia and their caregivers displayed a significant economic and humanistic burden. While severe patients showed the highest direct medical and societal costs, and worse HRQoL, the burden of moderate haemophilia on its own was substantial and far from negligible.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available